Eagle’s Eye View: Your Weekly CV Update from ACC.org (Week of Oct. 31)
In this week’s View, Dr. Eagle discusses a secondary analysis of the REPRISE III randomized clinical trial on long-term outcomes of transcatheter aortic valve replacement with the Lotus valve vs the CoreValve/EvolutR, then looks at iron deficiency and cardiovascular disease. Finally, Dr. Eagle explores the association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation.